Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 29

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 29
---
 NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market, the OTC QX, the OTC
QB or the Over-the-Counter Bulletin Board, then the Company or any successor entity will pay at the holder’s option, exercisable
at any time concurrently with or within 30 days after the consummation of the fundamental transaction, an amount of cash equal to the
value of the February Placement Agent Warrant as determined in accordance with the Black Scholes option pricing model.

Transferability. Each
placement agent warrant and all rights thereunder are transferable, in whole or in part, upon surrender of the placement agent warrant,
together with a written assignment of the warrant subject to applicable securities laws; provided, however, that the placement agent warrants
are subject to certain FINRA transfer restrictions. We do not intend to apply for listing of the placement agent warrants on any securities
exchange or other trading system.

No Rights as Shareholder Until Exercise. Except as set forth in the placement agent warrants, the holders of the placement agent
warrants do not have any voting rights, dividends or other rights as a holder of our capital stock until they exercise the placement agent
warrants.

Series D Warrants and May 2023 Placement Agent Warrants

The following is a brief summary of the Series D Warrants and the placement agent
warrants, or the May 2023 Placement Agent Warrants, issued in connection with a May 2023 registered direct offering, or May 2023 Registered
Direct Offering, and is subject in all respects to the provisions contained in the applicable warrants, which, are filed as exhibits to
this Registration Statement on Form F-1. Unless otherwise stated, references to warrants in this subsection include the Series D Warrants
and the May 2023 Placement Agent Warrants.

Exercisability.
The warrants became exercisable on June 14, 2023. The Series D Warrants and May 2023
Placement Agent Warrants expire five years and three years, respectively, from the initial exercise date. The holder shall deliver the
aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise
(subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. The Series D Warrants and May 2023 Placement Agent Warrants may be exercised on a cashless basis, if and only if, we
have not filed a registration statement